KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.

Jorge E Cortes, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow-Tee Goh, Philipp le Coutre, Gabriel Etienne, Inho Kim, David J Andorsky, Felice Bombaci, Ghayas C Issa, Naoto Takahashi, Shruti Kapoor, Rajendra Jinwal, Kamel Malek, Tracey McCulloch, Lillian Yau, Richard A Larson, Andreas Hochhaus

Blood 147(13) 1433-1446

PMID41397287
PMCIDPMC13123421
DOI10.1182/blood.2025029210
发表日期2025-12-15
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 1.:图注未提示 KM 曲线;Figure 2.:图注未提示 KM 曲线。
摘要

摘要

Many patients receiving frontline tyrosine kinase inhibitors (TKIs) for chronic-phase chronic myeloid leukemia (CML-CP) experience inadequate disease control and/or adverse events (AEs) that impair quality of life. Treatments offering optimal efficacy, safety, and tolerability will support long-term therapy. In the primary analysis from the ASC4FIRST trial, a phase 3 randomized trial comparing asciminib with investigator-selected TKIs (IS-TKIs) in newly diagnosed CML-CP, asciminib demonstrated superior efficacy vs all IS-TKIs and vs imatinib in the imatinib stratum, meeting both primary objectives. In the secondary analysis (2.2 years' median follow-up), major molecular response (MMR) rate at week 96 was 74.1% with asciminib vs 52.0% with IS-TKIs (treatment difference, 22.4% [95% confidence interval (CI), 13.6-31.3]; 1-sided P< .001) and 76.2% with asciminib vs 47.1% with imatinib in the imatinib stratum (treatment difference, 29.7% [95% CI, 17.6-41.8]; 1-sided P< .001), meeting both key secondary objectives. MMR rate was 72.0% with asciminib vs 56.9% with second-generation (2G) TKIs (treatment difference, 15.1% [95% CI, 2.3-28.0]; 1-sided P< .05), suggesting possible clinical benefit, although the study was not designed to formally confirm statistical significance for this secondary end point. Safety/tolerability remained favorable with asciminib vs IS-TKIs. Dose reductions and interruptions, respectively, occurred with asciminib (18.5%; 46.5%), imatinib (23.2%; 47.5%), and 2G TKIs (54.9%; 63.7%). The hazard ratio for time to discontinuation of treatment due to AEs for asciminib vs 2G TKIs was 0.46 (95% CI, 0.215-0.997). With longer follow-up, asciminib continued to demonstrate a favorable benefit-risk profile over IS-TKIs and imatinib, supporting its potential as a treatment option for newly diagnosed CML-CP. This trial was registered at www.clinicaltrials.gov as NCT04971226.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.The cumulative incidence of MMR is presented for all asciminib vs all IS-TKIs (A), asciminib vs imatinib in the imatinib stratum (B), and asciminib vs 2G TKIs in the 2G TKI stratum (C). ∗Nonresponders were censored at their last molecular assessment date. †Discontinuation from treatment for any reason without previous achievement of MMR was considered a competing event. Adapted from Cortes et al. 31
非 KM Figure
Figure 2.TTDAE is presented for asciminib vs 2G TKIs in the 2G TKI stratum (A), all asciminib vs all IS-TKIs (B), and asciminib vs imatinib in the imatinib stratum (C). ∗Event of interest is discontinuation of study treatment due to AE, including death due to AE. †Discontinuations of study treatment due to reasons other than AEs, including death due to other reasons, were the competing risks. Adapted from Cortes et al. 31
非 KM Figure